Krilogy Financial’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-3,131
Closed -$632K – 241
2023
Q1
$632K Buy
3,131
+894
+40% +$203K 0.05% 232
2022
Q4
$487K Sell
2,237
-607
-21% -$133K 0.05% 253
2022
Q3
$560K Buy
2,844
+44
+2% +$9.5K 0.07% 188
2022
Q2
$599K Buy
2,800
+264
+10% +$64.5K 0.07% 184
2022
Q1
$720K Sell
2,536
-1,043
-29% -$322K 0.07% 160
2021
Q4
$1.35M Sell
3,579
-33
-0.9% -$12.8K 0.14% 105
2021
Q3
$1.49M Sell
3,612
-33
-0.9% -$13.7K 0.15% 98
2021
Q2
$1.35M Sell
3,645
-123
-3% -$41.1K 0.13% 106
2021
Q1
$1.09M Buy
3,768
+733
+24% +$204K 0.12% 117
2020
Q4
$758K Buy
3,035
+114
+4% +$27.1K 0.09% 144
2020
Q3
$661K Buy
+2,921
New +$606K 0.09% 140
2020
Q1
– Sell
-4,799
Closed -$733K – 204
2019
Q4
$733K Buy
4,799
+61
+1% +$8.45K 0.12% 101
2019
Q3
$627K Buy
4,738
+753
+19% +$101K 0.11% 102
2019
Q2
$565K Buy
3,985
+533
+15% +$72.3K 0.11% 102
2019
Q1
$501K Buy
+3,452
New +$454K 0.11% 104

Other funds holding CRL

Krilogy Financial's CRL Position: Q2 2023 in Review

Krilogy Financial sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 3,131 shares — an estimated $632K sold.

Krilogy Financial first reported a position in CRL in Q1 2019 and held it in 15 quarters. The position peaked at $1.49M in Q3 2021. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

  • Krilogy Financial reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
  • Krilogy Financial sold 3,131 Charles River Laboratories shares in Q2 2023, an estimated $632K.
  • Krilogy Financial first reported a position in Charles River Laboratories in Q1 2019 and held it in 15 quarters.
  • Krilogy Financial's Charles River Laboratories position peaked at $1.49M in Q3 2021.
  • 611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Krilogy Financial's 13F filing for Q2 2023, filed 19 Jul 2023.